Literature DB >> 2869416

The benzazepine SCH 23390 increases plasma levels of cortisol in the conscious dog.

M Goiny, M Herrera-Marschitz, K Uvnäs-Moberg, S Cekan, U Ungerstedt.   

Abstract

The effect of neuroleptics on the hypothalamopituitary-adrenal system has been early recognized, but never adequately related to antipsychotic or side effects produced by dopamine antagonists. We are now presenting results showing that the newly characterized dopamine D-1 receptor antagonist, SCH 23390 (0.1 mg/kg i.v.) as well as the mainly dopamine D-2 receptor antagonists, haloperidol (0.1 mg/kg i.v.) and chlorpromazine (1 mg/kg i.v.), produced an increase of cortisol levels (108, 144 and 226% respectively, 20 min after the injection) determined by radioimmunoassay in blood samples collected from superficial veins of the legs of conscious dogs. The 5-HT2 receptor antagonist, cyproheptadine (0.2 mg/kg i.v.), did not modify the cortisol levels. These results suggest that cortisol increase is an effect common to neuroleptic compounds, independently of their relative antagonistic action at dopamine D-1 or D-2 receptors.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2869416     DOI: 10.1007/bf00633207

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  8 in total

Review 1.  Corticotrophin releasing factor.

Authors:  J C Buckingham
Journal:  Pharmacol Rev       Date:  1979-12       Impact factor: 25.468

2.  Reserpine- and chlorpromazine-induced changes in hypothalamo-hypophyseal-adrenal system in rats in the presence and absence of hypothermia.

Authors:  A N Bhattacharya; B H Marks
Journal:  J Pharmacol Exp Ther       Date:  1969-01       Impact factor: 4.030

3.  5HT-receptor antagonist properties of SCH 23390 in vascular smooth muscle and brain.

Authors:  P E Hicks; H Schoemaker; S Z Langer
Journal:  Eur J Pharmacol       Date:  1984-10-15       Impact factor: 4.432

4.  Relationship of neuroleptic drug effects at brain dopamine, serotonin, alpha-adrenergic, and histamine receptors to clinical potency.

Authors:  S J Peroutka; S H Synder
Journal:  Am J Psychiatry       Date:  1980-12       Impact factor: 18.112

5.  SCH 23390 - the first selective dopamine D-1 antagonist.

Authors:  J Hyttel
Journal:  Eur J Pharmacol       Date:  1983-07-15       Impact factor: 4.432

6.  Influence of haloperidol on ACTH and beta-endorphin secretion in the rat.

Authors:  P Giraud; J C Lissitzky; B Conte-Devolx; P Gillioz; C Oliver
Journal:  Eur J Pharmacol       Date:  1980-03-21       Impact factor: 4.432

7.  Effects of apomorphine and haloperidol on plasma cortisol levels in conscious dogs.

Authors:  K Uvnäs-Wallensten; M Goiny; M A Oriowo; S Cekan
Journal:  Acta Physiol Scand       Date:  1981-07

8.  SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.

Authors:  L C Iorio; A Barnett; F H Leitz; V P Houser; C A Korduba
Journal:  J Pharmacol Exp Ther       Date:  1983-08       Impact factor: 4.030

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.